Exubera Partnership In Doubt: Pfizer, Sanofi In Litigation Over Inhaled Insulin
This article was originally published in The Pink Sheet Daily
Executive Summary
Pfizer is seeking to enforce "change-in-control" provisions in the Exubera co-marketing agreement. Sanofi-Aventis says it "has no idea" if Pfizer's goal is to buy out the partnership or force a sale to Sanofi.
You may also be interested in...
Exubera Inhaled Insulin User Fee Deadline Is January 2006
Pfizer and Sanofi-Aventis filed the Exubera NDA March 1; an early 2006 approval is based on a standard 10-month review. The companies expected to submit an NDA in 2001, but were delayed by pulmonary safety questions.
Exubera Inhaled Insulin User Fee Deadline Is January 2006
Pfizer and Sanofi-Aventis filed the Exubera NDA March 1; an early 2006 approval is based on a standard 10-month review. The companies expected to submit an NDA in 2001, but were delayed by pulmonary safety questions.
Exubera U.S. Regulatory Update Coming Soon, Pfizer Says
Pfizer believes it soon will be in a position to provide a regulatory update on the status of inhaled insulin. Company cites its Exubera partnership with Sanofi-Aventis and Nektar as an example of successful collaboration, although questions about the “change-of-control” provision with Sanofi-Aventis remain.